HAINAN POLY PHARM. CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.54 CNY | -5.04% |
|
-38.95% | -66.67% |
| Jul. 05 | Hainan Poly Pharm. Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Jul. 01 | Hainan Poly Pharm's Gets Certification for Invasive Aspergillosis Drug | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 15,563 | 18,305 | 24,051 | 10,716 | 10,146 | 3,382 | - |
| Enterprise Value (EV) 1 | 15,563 | 18,305 | 24,051 | 10,716 | 10,146 | 3,382 | 3,382 |
| P/E ratio | 51.5 x | 44.6 x | 57.9 x | 27.4 x | 119 x | 5.98 x | 5.06 x |
| Yield | 0.39% | - | - | - | - | - | - |
| Capitalization / Revenue | 16,380,115 x | 15,400,831 x | 15,940,433 x | 5,932,290 x | 7,777,740 x | - | - |
| EV / Revenue | 16,380,115 x | 15,400,831 x | 15,940,433 x | 5,932,290 x | 7,777,740 x | - | - |
| EV / EBITDA | - | - | 44,304,622 x | 19,464,894 x | 44,843,311 x | - | - |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Price to Book | 13.6 x | - | 10 x | 4.01 x | 3.52 x | - | - |
| Nbr of stocks (in thousands) | 420,988 | 436,989 | 436,980 | 434,540 | 448,538 | 448,542 | - |
| Reference price 2 | 36.97 | 41.89 | 55.04 | 24.66 | 22.62 | 7.540 | 7.540 |
| Announcement Date | 2/26/20 | 4/23/21 | 4/13/22 | 4/24/23 | 7/5/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales | 950.1 | 1,189 | 1,509 | 1,806 | 1,304 | - | - |
| EBITDA | - | - | 542.9 | 550.5 | 226.3 | - | - |
| EBIT | 333.5 | 457.8 | 468.1 | 439.5 | 47.89 | - | - |
| Operating Margin | 35.1% | 38.52% | 31.02% | 24.33% | 3.67% | - | - |
| Earnings before Tax (EBT) | 334.2 | 454.2 | 467.5 | 438.9 | 74.82 | - | - |
| Net income 1 | 301.1 | 407.5 | 416.6 | 420.6 | 85.92 | 571 | 674 |
| Net margin | 31.7% | 34.28% | 27.61% | 23.29% | 6.59% | - | - |
| EPS 2 | 0.7179 | 0.9400 | 0.9500 | 0.9000 | 0.1900 | 1.260 | 1.490 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | 0.1436 | - | - | - | - | - | - |
| Announcement Date | 2/26/20 | 4/23/21 | 4/13/22 | 4/24/23 | 7/5/24 | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | 29.7% | 24% | 17.9% | 15.6% | 3.33% | - | - |
| ROA (Net income/ Total Assets) | - | 17.1% | - | - | - | - | - |
| Assets 1 | - | 2,388 | - | - | - | - | - |
| Book Value Per Share | 2.720 | - | 5.500 | 6.150 | 6.430 | - | - |
| Cash Flow per Share | 0.5100 | 0.7600 | 0.3600 | 1.220 | 0.2500 | - | - |
| Capex | 402 | 836 | 803 | 1,037 | 537 | - | - |
| Capex / Sales | 42.31% | 70.37% | 53.25% | 57.4% | 41.14% | - | - |
| Announcement Date | 2/26/20 | 4/23/21 | 4/13/22 | 4/24/23 | 7/5/24 | - | - |
1CNY in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
7.54
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -66.67% | 465M | |
| +61.22% | 846B | |
| +40.12% | 628B | |
| -4.66% | 360B | |
| +16.77% | 322B | |
| +8.50% | 297B | |
| +14.11% | 240B | |
| +17.67% | 223B | |
| +2.74% | 224B | |
| +11.68% | 173B |
- Stock Market
- Equities
- 300630 Stock
- Financials Hainan Poly Pharm. Co., Ltd
